Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283065939> ?p ?o ?g. }
- W4283065939 endingPage "1959" @default.
- W4283065939 startingPage "1959" @default.
- W4283065939 abstract "Ocrelizumab is a B-cell-depleting monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and active primary progressive MS (aPPMS). This prospective, uncontrolled, open-label, observational study aimed to assess the efficacy of ocrelizumab in patients with aPPMS and to dissect the clinical, radiological and laboratory attributes of treatment response. In total, 22 patients with aPPMS followed for 24 months were included. The primary efficacy outcome was the proportion of patients with optimal response at 24 months, defined as patients free of relapses, free of confirmed disability accumulation (CDA) and free of T1 Gd-enhancing lesions and new/enlarging T2 lesions on the brain and cervical MRI. In total, 14 (63.6%) patients and 13 patients (59.1%) were classified as responders at 12 and 24 months, respectively. Time exhibited a significant effect on mean absolute and normalized gray matter cerebellar volume (F = 4.342, p = 0.23 and F = 4.279, p = 0.024, respectively). Responders at 24 months exhibited reduced peripheral blood ((%) of CD19+ cells) plasmablasts compared to non-responders at the 6-month point estimate (7.69 ± 4.4 vs. 22.66 ± 7.19, respectively, p = 0.043). Response to ocrelizumab was linked to lower total and gray matter cerebellar volume loss over time. Reduced plasmablast depletion was linked for the first time to sub-optimal response to ocrelizumab in aPPMS." @default.
- W4283065939 created "2022-06-19" @default.
- W4283065939 creator A5002127327 @default.
- W4283065939 creator A5014403258 @default.
- W4283065939 creator A5014936275 @default.
- W4283065939 creator A5026826860 @default.
- W4283065939 creator A5026841977 @default.
- W4283065939 creator A5028176205 @default.
- W4283065939 creator A5035846144 @default.
- W4283065939 creator A5038273013 @default.
- W4283065939 creator A5038978833 @default.
- W4283065939 creator A5039252203 @default.
- W4283065939 creator A5041737944 @default.
- W4283065939 creator A5042914297 @default.
- W4283065939 creator A5050517426 @default.
- W4283065939 creator A5054924160 @default.
- W4283065939 creator A5066986016 @default.
- W4283065939 creator A5068040255 @default.
- W4283065939 date "2022-06-17" @default.
- W4283065939 modified "2023-09-26" @default.
- W4283065939 title "Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response" @default.
- W4283065939 cites W1512688389 @default.
- W4283065939 cites W1522374426 @default.
- W4283065939 cites W1587699581 @default.
- W4283065939 cites W1816536644 @default.
- W4283065939 cites W1936875239 @default.
- W4283065939 cites W1965380641 @default.
- W4283065939 cites W1976075786 @default.
- W4283065939 cites W1978385118 @default.
- W4283065939 cites W1981621288 @default.
- W4283065939 cites W1990110979 @default.
- W4283065939 cites W1992214067 @default.
- W4283065939 cites W1995353727 @default.
- W4283065939 cites W2004348520 @default.
- W4283065939 cites W2021279859 @default.
- W4283065939 cites W2023910475 @default.
- W4283065939 cites W2025663766 @default.
- W4283065939 cites W2038377404 @default.
- W4283065939 cites W2066470779 @default.
- W4283065939 cites W2086080135 @default.
- W4283065939 cites W2088980803 @default.
- W4283065939 cites W2105206040 @default.
- W4283065939 cites W2108193054 @default.
- W4283065939 cites W2112165124 @default.
- W4283065939 cites W2117650131 @default.
- W4283065939 cites W2125736142 @default.
- W4283065939 cites W2126284284 @default.
- W4283065939 cites W2126336004 @default.
- W4283065939 cites W2127534922 @default.
- W4283065939 cites W2141111992 @default.
- W4283065939 cites W2142577589 @default.
- W4283065939 cites W2147750230 @default.
- W4283065939 cites W2151863179 @default.
- W4283065939 cites W2152596071 @default.
- W4283065939 cites W2155779547 @default.
- W4283065939 cites W2158515030 @default.
- W4283065939 cites W2160872052 @default.
- W4283065939 cites W2162696934 @default.
- W4283065939 cites W2162978315 @default.
- W4283065939 cites W2170654913 @default.
- W4283065939 cites W2269460659 @default.
- W4283065939 cites W2271738643 @default.
- W4283065939 cites W2466829761 @default.
- W4283065939 cites W2476839077 @default.
- W4283065939 cites W2561881161 @default.
- W4283065939 cites W2565433170 @default.
- W4283065939 cites W2568723455 @default.
- W4283065939 cites W2596508435 @default.
- W4283065939 cites W2726907951 @default.
- W4283065939 cites W2777074421 @default.
- W4283065939 cites W2791428368 @default.
- W4283065939 cites W2793439531 @default.
- W4283065939 cites W2896912757 @default.
- W4283065939 cites W2897523569 @default.
- W4283065939 cites W2899093568 @default.
- W4283065939 cites W2989833866 @default.
- W4283065939 cites W3010352714 @default.
- W4283065939 cites W3014729659 @default.
- W4283065939 cites W3017957088 @default.
- W4283065939 cites W3031743028 @default.
- W4283065939 cites W3033968144 @default.
- W4283065939 cites W3045566727 @default.
- W4283065939 cites W3053671123 @default.
- W4283065939 cites W3080772091 @default.
- W4283065939 cites W3084818633 @default.
- W4283065939 cites W3090416272 @default.
- W4283065939 cites W3092834720 @default.
- W4283065939 cites W3101887247 @default.
- W4283065939 cites W3114336828 @default.
- W4283065939 cites W3120882765 @default.
- W4283065939 cites W3151536336 @default.
- W4283065939 cites W3160002009 @default.
- W4283065939 cites W3166691858 @default.
- W4283065939 cites W3171747481 @default.
- W4283065939 cites W3190957947 @default.
- W4283065939 cites W3193675201 @default.
- W4283065939 cites W3200661632 @default.
- W4283065939 cites W3205097850 @default.